Previous page

Collaborations

Vivomicx is actively looking for R&D, Technology & Marketing partners.

We gladly collaborate to expand the application area of our technology beyond kidney related diseases, angiogenesis and oncology, to cover other disease areas like i.e. cardiovascular disease and CNS.

We are also interested in co-development partners with relevant expertise to assist us in developing our technology further as a system to be integrated as a screening mechanism in the process of drug discovery & drug development.

Last but not least we like to be in contact with partners that can help us to expand our reach towards potential customers. Companies that see the added value of offering the Vivomicx deep tissue analysis to their customer base.

 

For more information or partnership offers: j.zuidema@vivomicx.eu

Current collaboration TAmiRNA

TAmiRNA & Vivomicx have combined their technologies of laser microdissection and high sensitivity qPCR, which enables the quantitative analysis of cell-type specific RNA expression in complex tissues.

Vienna, Austria and Groningen, The Netherlands (January, 2018)

TAmiRNA GmbH and Vivomicx BV today announce their collaboration to make the trajectory of preclinical drug discovery & development more efficient by providing more in-depth information from preclinical tissue samples. The collaboration covers joint marketing and joint execution of preclinical testing combining the expertise of both companies. TAmiRNA & Vivomicx have combined their technologies of laser microdissection and high sensitivity qPCR, which enables the quantitative analysis of cell-type specific RNA expression in complex tissues.

Using this protocol TAmiRNA & Vivomicx have already been able to demonstrate:

  1. the profound difference of RNA expression between whole tumor and subsets of cells within the tumor and
  2. the large heterogeneity in RNA expression between colorectal* tumor compartments such as tumor, stroma and tumor endothelial cells.

* Note: the technology can be utilized for almost any tissue sample.

The combination of Vivomicx and TAmiRNA´s proprietary protocols is clearly superior to the current standard where only whole tumor material is analyzed, and marks another step on the road to make the drug development process more efficient and therefore less costly.

This technique allows to

  • Gain better understanding of drug mode of actions by analyzing effects of therapeutic interventions on one cell type within the complexity of the tissue.

  • Improve the discovery and characterization of lead drug candidates based on enrichment of their targets in specific (tumor) tissue compartments.

  • Quantify drug-target engagement in specific cell types in complex tissue through the screening of downstream effects on gene expression level.

  • Characterize the differences between malignant and benign tissue on a cell-type specific level.

  • Identify novel biomarkers for patient selection as well as diagnosis and monitoring of disease progression and drug effects.

 

TAmiRNA specializes in technologies for profiling levels of blood-circulating microRNAs and developing multi-parametric classification algorithms (“signatures”). TAmiRNA uses these technologies to develop minimal-invasive diagnostic tests for drug development, early diagnosis and prognosis of disease, and as companion diagnostic tests to support treatment decisions.

 

Vivomicx has developed validated protocols to analyze preclinical or clinical tissue samples using Laser Dissection Microscopy in combination with Quantitative RT-PCR analysis. This allows the in-depth analysis of gene expression in subsets of cells in the complexity of the in vivo tissue. Using this technology we can assess gene expression profiles and therefore the molecular identity of cells; e.g. is your target molecule expressed in the cells of interest in diseased tissue? On top of that we can determine the true effects of a drug on mRNA expression levels in the cells of interest; e.g. what is the effect of your drug in terms of target inhibition and/or downstream effector modulation.

 

For more information contact:

 

Jan Zuidema , CBO & Co-founder  

j.zuidema@vivomicx.eu 

Tel. +31621124552

www.vivomicx.eu

 

or

 

Dr. Matthias Hackl, CEO

info@tamirna.com

Tel. +436604205856

www.tamirna.com

Current collaboration Vera Salus Richerca

Vera Salus Ricerca and Vivomicx collaborate to generate more in-depth information from preclinical tissue samples.

Siracusa/Sicily, Italy and Groningen, The Netherlands (October 2017)

Vera Salus Ricerca Srl and Vivomicx BV today announce their collaboration to make the trajectory of preclinical drug discovery & development more efficient by providing more in-depth information from the preclinical tissue samples. The collaboration covers joint marketing and joint execution of preclinical testing combining the expertise of both companies.

Vera Salus Ricerca is a biotech discovery company specialized in the design, planning and execution of in vitro and in vivo testing to support the preclinical development of drugs and companion diagnostics. Outstanding in house expertise and state-of-the-art protocols are leveraged to facilitate all clients’ needs in drug discovery, molecular pharmacology, signalling pathway elucidation and precision therapeutics.

Vivomicx has developed validated protocols to analyze preclinical or clinical tissue samples using Laser Dissection Microscopy in combination with Quantitative RT-PCR analysis. This allows the in-depth analysis of gene activity in subsets of cells in the complexity of the in vivo tissue. Using this technology we can assess gene expression profiles and therefore the molecular identity of cells; e.g. is your target molecule expressed in the cells of interest in diseased tissue? On top of that we can determine the true effects of a drug on mRNA expression levels in the cells of interest; e.g. what is the effect of your drug in terms of target inhibition and/or downstream effector modulation.

 

For more information contact:

 

Jan Zuidema

CBO & Co-founder Vivomicx

j.zuidema@vivomicx.eu

Tel. +31621124552

www.vivomicx.eu

 

or

 

Giovanni Mario Pitari, M.D., Ph.D.

R&D Director, Founder

giovanni.pitari@verasalusricerca.it

Tel. +393342200240

www.verasalusricerca.it

Current collaboration MTT Labs

Vivomicx & MTT Labs collaborate to make the trajectory of preclinical drug discovery & development more efficient

MTTlab Srl and Vivomicx BV have come together to make the trajectory of preclinical drug discovery & development more efficient by providing more in-depth information from the preclinical tissue samples. The collaboration covers joint marketing and joint execution of preclinical testing combining the expertise of both companies.

 

MTTlab delivers both in vitro and in vivo data sets for the preclinical evaluation of an investigational compound which can be used for regulatory submissions, project evaluation, scientific publications and fundraising. MTTlab provides support for our clients’ studies or projects from the earliest stages and assists with both scientific and regulatory challenges to obtain valid results within requested deadlines.

 

Vivomicx has developed validated protocols to analyze preclinical or clinical tissue samples using Laser Dissection Microscopy in combination with Quantitative RT-PCR analysis. This allows the in-depth analysis of gene activity in subsets of cells in the complexity of the in vivo tissue. Using this technology we can assess gene expression profiles and therefore the molecular identity of cells; e.g. is your target molecule expressed in the cells of interest in diseased tissue? On top of that we can determine the true effects of a drug on mRNA expression levels in the cells of interest; e.g. what is the effect of your drug in terms of target inhibition and/or downstream effector modulation.

Current collaboration Synvolux

Vivomicx is collaborating in the field of targeted siRNA delivery with Synvolux.

Vivomicx technology analyses in vivo local knock down of genes that is created by selective delivery of siRNA into target (endothelial) cells, and hence assists in showing proof delivery success. Furthermore, it provides clues for downstream consequences of gene knock out in the complex in vivo environment.

More information about the research in this particular collaboration can be found in: Kowalski PS, Zwiers PJ, Morselt HWM, Kuldo JM, Leus NGJ, Ruiters MHJ, Molema G, Kamps JAAM (2014). Anti-VCAM-1 SAINT-O-Somes enable endothelial-specific delivery of siRNA and downregulation of inflammatory genes in activated endothelium in vivo. Journal of Controlled Release; 176: 64 - 75.

Vivomicx: Better drugs faster

Interested?

Please contact us !